Skip to content
Research ReviewFact-checked March 2026

MOTS-c: Exercise in a Vial — The Mitochondrial Peptide Changing Metabolic Science

MOTS-c is a 16-amino acid peptide encoded within mitochondrial DNA — one of the first mitochondria-derived signalling molecules ever discovered. At the Salk Institute, injection alone increased running endurance in sedentary mice by 44%. In 2026, MOTS-c represents the frontier of metabolic...

Evidence strength

Level 4

Case series / Animal studies

Peer-reviewed refs

3

Reading time

11 min

Key Takeaways

  • MOTS-c is the first peptide proven to be encoded within mitochondrial DNA — a discovery that fundamentally changed understanding of mitochondrial biology.
  • Circulating MOTS-c is lower in older men, while skeletal-muscle MOTS-c expression is higher — a plausible ageing-related marker, not yet a validated longevity biomarker.
  • Activates AMPK through a pathway independent of cellular energy status — producing metabolic adaptation even when energy is not depleted.
  • Safety profile: limited human data. Monitor blood glucose during use — additive with any glucose-lowering intervention. Not for use with metformin without medical supervision.

The Discovery That Changed Mitochondrial Biology

For decades, mitochondria were understood as passive energy factories — organelles that convert nutrients to ATP through a fixed set of processes. The discovery of MOTS-c in 2015 by Lee et al. at USC forced a fundamental revision of this model.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded entirely within the 12S ribosomal RNA gene of mitochondrial DNA. It is the first peptide proven to be produced by mitochondria themselves — not by the nuclear genome — establishing that mitochondria are not passive factories but active signalling organs that communicate their metabolic state to the rest of the cell and even to the nucleus.

[1]

The Salk Institute Endurance Data

The most striking experimental finding: sedentary mice given MOTS-c injections for one week, without any exercise training, showed a 44% increase in running endurance compared to controls. Their muscles showed gene expression changes characteristic of trained athletes — increased fatty acid oxidation capacity, improved mitochondrial efficiency, and reduced lactate accumulation.

This is the basis for the "exercise in a vial" description. MOTS-c does not replace exercise — but it activates some of the same metabolic adaptations that exercise produces, through the same AMPK-mediated pathways.

Mechanism: A Unique AMPK Activation Pathway

AMPK (AMP-activated protein kinase) is the master metabolic regulator — the cellular sensor that triggers fat burning, glucose uptake, and mitochondrial biogenesis in response to energy deficit. Exercise activates AMPK by depleting ATP (raising the AMP:ATP ratio). Caloric restriction activates it by reducing glucose availability.

MOTS-c activates AMPK through neither of these mechanisms. It acts upstream of the AMP/ATP ratio, through a pathway that involves the folate cycle and purine biosynthesis. This means MOTS-c can activate AMPK even when the cell is well-nourished and well-rested — producing metabolic adaptation without energy deficit.

[1]

Nuclear translocation: Under metabolic stress, MOTS-c translocates from the cytoplasm directly into the cell nucleus, where it regulates gene expression. This makes it one of a very small number of peptides that directly influence nuclear gene programmes.

[2]

The Longevity Biomarker Evidence

A cross-sectional study of healthy men measured MOTS-c in plasma and skeletal muscle across age groups. Circulating MOTS-c was lower with age, yet middle-aged (45–55 y) and older (70–81 y) men had ~1.5-fold higher MOTS-c expression in muscle than young men (18–30 y), and in older men muscle MOTS-c was associated with slow-type fibres and better muscle quality.

Plasma and muscle MOTS-c therefore appear to be regulated differently with ageing. That makes MOTS-c a plausible ageing-related marker, but it is not yet a validated longevity biomarker.

[3]

Practical Protocol

MOTS-c alone:

  • 10mg subcutaneous, 3-5 times per week
  • Morning timing (aligns with natural metabolic rhythms)
  • 4-8 week cycles, 4 weeks off

Metabolic Optimizer Stack (see full protocol):

  • NMN (Nicotinamide Mononucleotide) 500mg daily — provides NAD+ that AMPK pathways utilise
  • MOTS-c 10mg SC, 3x/week (Monday, Wednesday, Friday)
  • AICAR (Acadesine) 50mg SC, 2x/week (Tuesday, Thursday) — alternated to avoid same-day stacking
  • Monitor glucose on AICAR days especially

Blood glucose monitoring is mandatory for the full Metabolic Optimizer stack — particularly when combining MOTS-c with AICAR. Both lower glucose through AMPK activation; the combination can produce meaningful hypoglycaemia in susceptible individuals.

Where MOTS-c Sits in Its Family

MOTS-c is one of a class of mitochondrial-derived peptides; the first, humanin, was found in 2001. The class as a whole — and the fact that neither peptide has a published human administration trial — is covered in Humanin and MOTS-c: Mitochondrial-Derived Peptides Explained. The other compound sold as an "exercise mimetic" works through nuclear receptors rather than AMPK and is reviewed in SLU-PP-332: The Exercise Mimetic Research Update. For a plan that puts training first and treats MOTS-c as an optional experimental layer, see The Advanced Mitochondrial Stack.

Scientific References

  1. [1]
    Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Cell Metabolism (2015)Oxford 4
    PMID 25738459
  2. [2]
    Kim KH, Son JM, Benayoun BA, et al.. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress — Cell Metabolism (2018)Oxford 5
    PMID 29983246
  3. [3]
    D'Souza RF, Woodhead JST, Hedges CP, et al.. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition — Aging (2020)Oxford 2b
    PMID 32182209

Follow us on Google Search

Add BiohackingHub as a preferred source to see more of our research in Google results.

Ad slot available · 728×90Advertise here

Related protocols

Partner with BiohackingHub

Editorial placements, sponsorships, and product features for evidence-minded brands.

Partnership opportunities →